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Abstract
Chondroitin 6-sulfotransferase (C6ST) is the key enzyme in the biosynthesis of chondroitin 6-sulfate, a glycosaminoglycan
implicated in chondrogenesis, neoplasia, atherosclerosis, and other processes. C6ST catalyzes the transfer of sulfate from 3P-
phosphoadenosine 5P-phosphosulfate to carbon 6 of the N-acetylgalactosamine residues of chondroitin. Based on the
previously published avian sequence, we searched the database of expressed sequence tags (dbEST) and obtained partial-
length cDNAs that we completed by 5P-RACE using human chondrosarcoma and endothelial-cell RNA as template. Stable
transfection of our full-length expression construct into CHO-K1 cells resulted in marked increases in C6ST and keratan
sulfate sulfotransferase (KSST) enzymatic activities in cell homogenates. The predicted 411 amino acid sequence of human
C6ST contains an N-terminal hydrophobic domain consistent with membrane insertion, four potential sites for N-linked
glycosylation, several consensus sequences for protein phosphorylation, and one RGD sequence. The human and chick C6ST
cDNA share 51% nucleotide identity, 40% amino acyl identity, and 75% amino acyl conservation. The human C6ST gene
structure has been elucidated and exhibits an intron-less coding region, and the gene has been mapped to human
chromosome 11 by radiation hybrid panel mapping. z 1998 Elsevier Science B.V. All rights reserved.
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Chondroitin sulfate proteoglycans are ancient and
widespread components of the cell surface and ex-
tracellular matrix of animals. Chondroitin 6-sulfate
(C6S), which is sulfated at carbon 6 of the N-acetyl-
galactosamine residues, has been implicated in sev-
eral key roles in human biology. The key enzyme in
its biosynthesis, C6ST, catalyzes the transfer of sul-
fate from 3P-phosphoadenosine 5P-phosphosulfate
(PAPS) to position 6 of N-acetylgalactosamine resi-
due of chondroitin. The same enzyme in the chick
has also been shown to possess keratan sulfate sulfo-
transferase (KSST) activity, i.e. it catalyzes the trans-
fer of sulfate from PAPS to carbon 6 of the galactose
residues of keratan sulfate [1^3]. In humans, a de¢-
ciency in C6ST activity has been associated with a
heritable form of spondyloepiphyseal dysplasia, thus
implicating this enzyme in normal skeletal develop-
ment [4,5]. It has been shown that the connective
tissue stroma of human colon carcinomas contains
increased amounts of unsulfated and 6-sulfated
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chondroitin and reduced 4-sulfated forms, compared
to the surrounding normal tissue [6]. Chondroitin
sulfate proteoglycans in the arterial matrix, particu-
larly 6-sulfated forms, have been implicated in arte-
rial retention of cholesterol-rich, atherogenic lipopro-
teins [7,8], a key event that initiates atherosclerosis
[9]. Importantly, the abundance of C6S is under ge-
netic [10] and stimulatory [11^16] control, but molec-
ular tools to study its function and regulation in
mammalian cells and tissues have been lacking.
Using the recently published chick cDNA se-
quence encoding C6ST [17], we performed a com-
puter search [18] of the database of expressed se-
quence tags (dbEST) of the IMAGE consortium
[19]. Three human sequences homologous to di¡erent
regions of the chick C6ST were identi¢ed (IMAGE
40604-5P, 48676-5P, and 53039-5P), and the corre-
sponding clones were purchased from Research Ge-
netics, (Huntsville, AL). The inserts were fully se-
quenced (Model 377 automated sequencing system
used with the DyeDeoxy Terminator Cycle sequenc-
ing kit, Applied Biosystem, Foster City, CA) and
found to di¡er only in their extent of 5P sequence.
The new human sequence information was used for
another computer search of the dbEST, which iden-
ti¢ed three additional clones (K676-f, 43289-3P, and
53039-3P). The inserts in these clones were identical
to the ¢rst three except for the extent of 5P sequence.
Thus, we have no evidence for a gene family. The
respective GenBank accession numbers for these
dbEST sequences are R55609, H16077, and R16177
for the ¢rst set and R41023, H05595, and R15740 for
the second set.
The longest insert was 1806 bp (IMAGE 53039-
5P), but it lacked a start codon. Therefore, we com-
pleted the sequence by 5P rapid ampli¢cation of
cDNA ends (5P-RACE system, Gibco, Gaithersburg,
MD), using RNA templates from human chondro-
sarcoma and human umbilical vein endothelial cells.
No sequence di¡erences were observed amongst
these sources. Sequences were assembled into a single
contig, which was analyzed for motifs [20] and com-
pared [21] with the avian sequence.
The human cDNA sequence contains a single open
reading frame of 1233 bp, corresponding to 411 ami-
no acyl residues, with a predicted molecular weight
of 46 714 Da (Fig. 1A). The unique in-frame start
codon is a strong initiation site for translation [22]
and is homologous to the second of two potential
start codons reported for the avian sequence [17].
Nucleotide sequences, including the 5P and 3P £ank-
ing regions, show 51% identity overall between the
two species. Predicted amino acyl sequences, using
the second potential avian start codon, show 40%
identity and 75% conservation between human and
chick. The human sequence contains an N-terminal
hydrophobic sequence that resembles a signal peptide
sequence [23], which might explain the presence of
this enzyme extracellularly (see [1,5,24]). Much of
this enzyme is intracellular (see below) in the Golgi
[25,26], and it is possible that this N-terminal se-
quence is actually a Golgi retention signal [27].
Like chick C6ST, the human molecule has several
potential sites for N-linked glycosylation [28]. Several
phosphorylation motifs, including two tyrosine kin-
ase phosphorylation sites [29,30], are present. Inter-
estingly, the human sequence, unlike the chick, con-
tains the RGD motif, which, if functional, would
bind integrins when the enzyme is outside the cell
[31].
To screen for human genomic clones, we used a 5P-
RACE clone to prepare a probe that contains the
¢rst 525 bp of our cDNA sequence. This probe
was used for automated screening of a human ge-
nomic P1 arti¢cial chromosome (PAC) library (Ge-
nome Systems, St. Louis, MO). In this library, the
PAC vector is 16.5 kb, and the genomic inserts are
typically V120 kb. Two clones were identi¢ed, with
clone addresses of PAC-18-L22 and PAC-189-O18,
and we con¢rmed their identi¢cation by Southern
blot of BamHI-generated fragments, hybridized
with probes made from 5P and 3P segments of the
C
Fig. 1. (A) The nucleotide sequence of the human C6ST cDNA and deduced amino acyl sequence. The N-terminal hydrophobic do-
main is underlined, with a triangle to indicate a consensus sequence for signal peptide cleavage. The four potential N-linked glycosyla-
tion sites are underlined. Tyrosine phosphorylation motifs are double underlined. The RGD sequence is overlined. The nucleotide se-
quence appears in the GenBank database under accession no. U65637. (B) Intron^exon boundary sequences. Intronic sequences are
shown in upper case, and exonic in lower case. The intron is located between cDNA bases 82 and 83.
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cDNA (data not shown). By sequencing the genomic
clones directly or PCR-generated genomic fragments,
we have found that the gene structure consists of an
initial exon limited to the 5P untranslated region
(UTR), an intron of 926 bp between cDNA bases
82 and 83, and then an exon that encodes the rest
of the 5P UTR plus the entire coding region and 3P
UTR. The termini of the intron (GT-AG) have been
con¢rmed by sequencing (Fig. 1B). Mammalian
genes with intron-less coding regions have been pre-
viously reported [32,33] and indicate a primitive
structure that precludes the generation of di¡erent
forms of the protein through alternative RNA splic-
ing. Genetic analyses for polymorphisms, however,
should be technically straight-forward [33].
We used one of the genomic clones as template for
PCR to amplify the entire C6ST coding region in one
piece, which we then ligated into the pcDNA3 ex-
pression vector (Invitrogen, San Diego, CA; eukary-
otic expression is driven by the CMV promoter).
This construct was introduced into CHO cells by
calcium-phosphate transfection [34], and stable trans-
fectants were selected with G418 (pcDNA3 contains
the neomycin resistance gene). As before [35], we
minimized artifacts from clonal variation by propa-
gating two mixed lines and four clonal lines. For
controls, we used wild-type CHO cells and one clonal
CHO line that had been transfected with an irrele-
vant cDNA, pFcR-Synd1 [35]. Expression of our
construct was veri¢ed by Northern blot, which
showed abundant message in all transfected cells,
but not in the controls (data not shown). Homoge-
nates of the cells were then prepared, and C6ST and
C4ST enzymatic activities were assessed by incuba-
tion in the presence of [35S]PAPS (the sulfate donor)
and unsulfated chondroitin (the sulfate acceptor),
followed by the complete enzymatic digestion of
the newly sulfated chondroitin into disaccharides
[17]. The labeled disaccharides, [35S]vDi-6S and
[35S]vDi-4S, which indicate the enzymatic activities
of C6ST and chondroitin 4-sulfotransferase (C4ST),
respectively, were then separated by thin-layer chro-
matography using plates coated with microcrystalline
cellulose (Analtech, Newark, DE) [36], and autora-
diography was performed using a PhosphorImager
(Molecular Dynamics, Sunnyvale, CA).
Fig. 2A indicates that the wild-type CHO cells (wt)
have abundant endogenous C4ST activity, yet very
little C6ST activity, consistent with prior reports that
the GAGs made by these cells have a low C6S:C4S
ratio [37]. The clonal control was exactly the same
(data not shown). In contrast, cell homogenates of
all mixed and clonal lines transfected with the C6ST
expression vector showed C6ST activity that was
equal to or greater than the C4ST activity. The in-
crease in the C6ST-to-C4ST ratio in the transfected
lines over control cells was up to 14-fold. Thus, this
cDNA encodes a human C6ST. Separate studies us-
ing keratan sulfate as the sulfate acceptor showed
that, as with the chick enzyme [17], the human mol-
ecule also possesses KSST activity (Fig. 2B). As an
Fig. 2. Sulfotransferase activities in homogenates of control and
C6ST-transfected CHO cells. (A) Chondroitin sulfotransferase
activities in homogenates of wild-type CHO cells (wt) and of
CHO cell lines stably transfected with the expression vector for
human C6ST (clonal lines, C1, C2, C3, C4 ; mixed lines, M2,
M3). 35S-Labeled products (vDi-6S and vDi-4S) and the origin
are marked. The spots that appear at the level of the origin in
lanes C1 and C2, but o¡-center, are markers placed after chro-
matography to locate the origin. (B) Keratan sulfate sulfotrans-
ferase activities in cell homogenates. Under these conditions,
35S-labeled keratan sulfate remains at the origin. (C) Control
incubations of cell homogenates with [35S]PAPS, but without
the addition of a sulfate acceptor. The contrast scale of this
panel is the same as in (B). Each lane in the three panels repre-
sents the enzymatic activity in 3.2 Wg of cell protein.
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additional control, incubations of cell homogenates
with [35S]PAPS but no sulfate acceptor showed es-
sentially no product (Fig. 2C).
Chromosomal localization of our human C6ST
gene has been completed by radiation hybrid panel
mapping [38,39], using information from the Ge-
nome Database (http://gdbwww.gdb.org). A com-
puter search of this database revealed that the
Radiation Hybrid Transcript Mapping Consortium
has analyzed two amplimers, stSG4330 and
stSG3611, that were based on one of the six dbEST
clones, clone R15740, that we had identi¢ed as con-
taining partial-length human C6ST cDNA sequence.
Using the Genebridge 4 panel, both of these am-
plimers were mapped to human chromosome 11.
To ¢nd the locations within chromosome 11, we sub-
mitted the radiation panel data vectors for a map-
ping run on the Whitehead framework map, an lod
2.5 map (http://www-genome.wi.mit.edu). The map-
ping runs localized the amplimers to the same region
of chromosome 11, namely, 4.5^6.51 centiRays (cR)
from WI-4635 (D11S2375), with lod scores s 3.0.
WI-4635 is a framework marker on the lod 2.5 map
that has been placed 163.56 cR from the top of the
chromosome 11 linkage group and is part of
WC11.4, a singly linked YAC contig. Examination
of chromosome 11 contigs anchored on the inte-
grated map (http://www-genome.wi.mit.edu) re-
vealed several nearby markers with simple sequence
repeats known or likely to be polymorphic. Thus,
these markers, or any other nearby polymorphic
markers, can be used in linkage studies.
Overall, these results provide necessary molecular
tools to investigate the regulation and the role of
C6S and C6ST in human physiology and disease.
During the review of this manuscript, a report of
this cDNA with its chromosomal location appeared
by Fukuta et al. [40], but with three signi¢cant di¡er-
ences from our results. First, although our sequence
was homologous to the entire length of the chick
C6ST cDNA, including the entire 5P UTR, the other
report contained an additional 242 bp of 5P UTR in
the human cDNA. Sequencing of our genomic DNA
has revealed additional introns in this larger 5P UTR.
Using Fukuta et al.s numbering, we have found in-
trons between cDNA bp 140 and 141, 226 and 227,
and 324 and 325 (the last of these is equivalent to
our bp 82 and 83). Second, although our computer-
ized search of the dbEST did not reveal any other
human cDNAs with strong homology to the chick
C6ST, Fukuta et al. mention the existence of a sec-
ond homologous human sequence, which they found
during their screening of a Vgt 11 human cDNA
library [40]. Third, and most important, our expres-
sion studies indicated both C6ST and KSST activ-
ities, as with the chick enzyme, whereas the results of
Fukuta et al. revealed a novel pattern of KSST ac-
tivity with no detectable C6ST activity [40]. Some of
this di¡erence might have arisen from our use of
stable transfection, which a¡ects essentially 100% of
the cells being assayed, in a cell line that has a very
low ratio of endogenous C6ST to C4ST activities (see
Fig. 2A and [37]), whereas Fukuta et al. used tran-
sient transfections in COS-7 cells, which have a high
endogenous ratio of C6ST to C4ST (see Table 1 in
[40]). The more intriguing possibility is that post-
translational processing may a¡ect C6ST activity
and that CHO cells and COS-7 cells exhibit key dif-
ferences in this regard. Of note, Fukuta et al. re-
ported the partial puri¢cation of KSST activity
with no contaminating C6ST activity in the unbound
fraction of transfected COS-7 cell homogenates sub-
jected to DEAE chromatography in 50 mM NaCl
(Fig. 3A in [40]). Our recent work indicates essen-
tially no enzymatic activity of either type in this frac-
tion from transfected CHO cell homogenates, i.e.,
over 95% of recovered C6ST and KSST activities
were retained on DEAE (data not shown). Studies
are currently underway in our laboratory to investi-
gate this di¡erence.
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